Shares of Puma Biotechnology soared more than 220% after the markets closed on Tuesday as investors cheered the biotech's positive Phase III numbers for a late-stage study of their lead drug neratinib (PB272).
Pfizer said Wednesday that it would buy New Jersey-based InnoPharma, for $225 million in cash and up to $135 million in contingent milestone payments.
The sterile injectables business holds promise for drugmakers with the manufacturing capabilities to produce the difficult-to-make drugs. Deals announced Wednesday by Pfizer and Sun Pharma were proof positive of how companies think they can cash in on the generics piece of this sterile injectables market.
What's #FOGO? Hint: Many of us have it. Another hint: Pfizer wants people to talk about it.
Face your fears. That's Pfizer's motto with its "Get Old" campaign, and the company is mounting a new push to get people talking about their fear of aging. On social media, no less, with a special #FOGO hashtag and a new digital advertising agency.
The court fight over Pfizer's stomach drug Reglan (metoclopramide) has yielded another ruling in Big Pharma's favor. Once again, a U.S. court has ruled that branded drugmakers can't be sued for damages allegedly caused by generic versions of their drugs.
Pfizer has a reputation for being a company that will cut jobs deeply once a merger is done, a rap that raised a lot of fears during its run at AstraZeneca. But the U.S. drugmaker can now point to about 100 jobs in Ireland that it is sparing as business has improved.
One hundred Irish Pfizer jobs once tapped for chopping are now safe, and the company's off-patent meds, like Lipitor, are the saviors.
With the expense of vaccine production often higher than the manufacturing costs for pharmaceuticals, vaccines once led losses for their manufacturers. But today, vaccines--like Pfizer's Prevnar 13, which scored more than $4 billion in worldwide sales last year--can be highly profitable.
A long-running and often contentious securities lawsuit tied to Pfizer's vilified pain drugs Celebrex and Bextra was set for a September trial, but is going into the dustbin of history instead. A federal judge in New York has dismissed the case a decade after it was filed and 9 weeks before proceedings were to commence.